debt_leverage_profile
0.00x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Minimal direct sensitivity; primary risk is higher discount rate compressing DCF valuation of pre-revenue biotech/MedTech equity
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Israeli medical-device component suppliers (geopolitical conflict risk) and Asian semiconductor/sensor manufacturers (Taiwan Strait chokepoint)
Inferred
Agent_Inference
international_expansion_readiness
Revenues near zero; primary market is Israel (ILS exposure); USD-denominated clinical trial costs offset ILS devaluation risk partially
Inferred
Agent_Inference
geographic_footprint
Predominantly Israel-based operations; ILS/USD cross-rate is primary FX risk; negligible multi-country revenue diversification currently
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on specialized oxygenation membrane and sensor suppliers; likely fewer than 3 qualified alternative vendors globally
Inferred
Agent_Inference
business_model_type_primary
Hardware-dependent MedTech; cloud disruption low-impact; AERS device operates on proprietary embedded systems, not public cloud infrastructure
Inferred
Agent_Inference
business_model_type_secondary
Potential future SaaS monitoring layer for patient data analytics; currently negligible; 30-day cloud termination would affect data dashboards only
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk currently; proprietary hardware-software integration creates high hospital switching costs once AERS is installed
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is product sales/licensing of medical devices; low Howey Test risk; no profit-sharing or investment-contract structure present
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Patient vital-signs data subject to HIPAA (US trials), GDPR (EU expansion); Israeli data protection law applies domestically; compliance costs material
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche oxygenation device market with established incumbents (Novalung, Getinge); market share too small to trigger scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional (device sales); estimated <10% recurring revenue from service contracts; pre-commercial stage limits recurring base
Inferred
Agent_Inference
monetization_vector
Capital equipment sale plus potential per-use consumable and service contract; recurring consumable revenue model targeted but not yet established
Inferred
Agent_Inference
pricing_architecture
Premium medical-device pricing (~$50K–$150K per unit estimated); reimbursement dependency on CPT code approval creates significant pricing uncertainty
Inferred
Agent_Inference
pricing_power_rating
Moderate; clinical differentiation (extracorporeal oxygenation without blood pump) supports premium, but hospital budget constraints limit pricing power
Inferred
Agent_Inference
target_gross_margin_bracket
450.0% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider problem; capital equipment purchase creates committed installed base; churn risk tied to clinical outcome data and reimbursement changes
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth largely sublinear to headcount; manufacturing scale-up requires some linear COGS labor, but R&D/SG&A leverage improves at scale
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost driven by hardware COGS and regulatory compliance; doubling revenue requires ~40–60% headcount increase, not 100%
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise model
Inferred
Agent_Inference
customer_acquisition_metric
CAC likely $200K–$500K per hospital system (clinical trial evidence, KOL engagement, procurement cycles); at 10x scale, CAC should decline 30–50%
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; clinical outcome data accumulation creates indirect data network effect improving regulatory and reimbursement positioning
Inferred
Agent_Inference
asset_efficiency_ratio
73.5% Return on Assets (Outstanding)
High
SEC-XBRL
recession_resistance_tier
Moderate-high resilience; acute respiratory failure treatment is non-discretionary; however, hospital capex freezes in recessions delay device purchases
Inferred
Agent_Inference
customer_segment_primary
ICU and critical care departments at tertiary hospitals; high concentration risk given early-stage limited customer base
Inferred
Agent_Inference
customer_segment_secondary
Military and emergency medicine applications; BARDA/DoD contracts could diversify but remain speculative at current stage
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
1.3% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001840292
Inferred
Agent_Inference
ticker
IINN
Inferred
Agent_Inference